141 related articles for article (PubMed ID: 30156754)
1. Additional Costs of Polymyalgia Rheumatica With Giant Cell Arteritis.
Mounié M; Pugnet G; Savy N; Lapeyre-Mestre M; Molinier L; Costa N
Arthritis Care Res (Hoboken); 2019 Aug; 71(8):1127-1131. PubMed ID: 30156754
[TBL] [Abstract][Full Text] [Related]
2. Incremental Costs in Giant Cell Arteritis.
Mounié M; Costa N; Sailler L; Lapeyre-Mestre M; Bourrel R; Savy N; Molinier L; Pugnet G
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1074-1081. PubMed ID: 28973818
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of self-reported diagnoses of polymyalgia rheumatica and giant cell arteritis in the French prospective E3N- EPIC cohort: A validation study.
Barde F; Ascione S; Pacoureau L; Macdonald C; Salliot C; Boutron-Ruault MC; Seror R; Nguyen Y
Semin Arthritis Rheum; 2024 Feb; 64():152298. PubMed ID: 38000317
[TBL] [Abstract][Full Text] [Related]
4. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
5. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica.
González-Gay MA; García-Porrúa C; Vázquez-Caruncho M
J Rheumatol; 1998 Sep; 25(9):1750-5. PubMed ID: 9733456
[TBL] [Abstract][Full Text] [Related]
6. Development of Giant Cell Arteritis after Treating Polymyalgia or Peripheral Arthritis: A Retrospective Case-control Study.
Liozon E; de Boysson H; Dalmay F; Gondran G; Bezanahary H; Fauchais AL; Ly KH
J Rheumatol; 2018 May; 45(5):678-685. PubMed ID: 29545449
[TBL] [Abstract][Full Text] [Related]
7. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms.
Mattey DL; Hajeer AH; Dababneh A; Thomson W; González-Gay MA; García-Porrúa C; Ollier WE
Arthritis Rheum; 2000 Aug; 43(8):1749-55. PubMed ID: 10943865
[TBL] [Abstract][Full Text] [Related]
8. Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study.
Paskins Z; Whittle R; Sultan AA; Muller S; Blagojevic-Bucknall M; Helliwell T; Hider S; Roddy E; Mallen C
BMC Med; 2018 Jan; 16(1):4. PubMed ID: 29316928
[TBL] [Abstract][Full Text] [Related]
9. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis.
Ungprasert P; Sanguankeo A; Upala S; Knight EL
Semin Arthritis Rheum; 2014 Dec; 44(3):366-70. PubMed ID: 25074657
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica.
Narváez J; Estrada P; López-Vives L; Ricse M; Zacarías A; Heredia S; Gómez-Vaquero C; Nolla JM
Semin Arthritis Rheum; 2015 Dec; 45(3):328-33. PubMed ID: 26186807
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis.
Chakravarty K; Pountain G; Merry P; Byron M; Hazleman B; Scott DG
J Rheumatol; 1995 Sep; 22(9):1694-7. PubMed ID: 8523347
[TBL] [Abstract][Full Text] [Related]
12. MMP-3 can distinguish isolated PMR from PMR with GCA: A retrospective study regarding PMR and GCA in Japan.
Fukui S; Nunokawa T; Kobayashi S; Kamei S; Yokogawa N; Takizawa Y; Shimada K; Sugii S; Setoguchi K
Mod Rheumatol; 2016; 26(2):259-64. PubMed ID: 26156043
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
Martinez-Taboada VM; Bartolome MJ; Fernandez-Gonzalez MD; Blanco R; Rodriguez-Valverde V; Lopez-Hoyos M
Rheumatology (Oxford); 2003 Sep; 42(9):1055-61. PubMed ID: 12730520
[TBL] [Abstract][Full Text] [Related]
14. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment.
Kyle V; Hazleman BL
Ann Rheum Dis; 1993 Dec; 52(12):847-50. PubMed ID: 8311533
[TBL] [Abstract][Full Text] [Related]
15. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.
Crowson CS; Matteson EL
Semin Arthritis Rheum; 2017 Oct; 47(2):253-256. PubMed ID: 28551169
[TBL] [Abstract][Full Text] [Related]
16. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A
Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445
[TBL] [Abstract][Full Text] [Related]
17. Familial aggregation of polymyalgia rheumatica and giant cell arteritis: genetic and T cell repertoire analysis.
Bartolome MJ; Martínez-Taboda VM; Lopez-Hoyos M; Blanco R; Rodriguez-Valverde V
Clin Exp Rheumatol; 2001; 19(3):259-64. PubMed ID: 11407077
[TBL] [Abstract][Full Text] [Related]
18. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data.
Pamuk ON; Dönmez S; Karahan B; Pamuk GE; Cakir N
Clin Exp Rheumatol; 2009; 27(5):830-3. PubMed ID: 19917168
[TBL] [Abstract][Full Text] [Related]
19. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients.
Hernández-Rodríguez J; Font C; García-Martínez A; Espígol-Frigolé G; Sanmartí R; Cañete JD; Grau JM; Cid MC
Medicine (Baltimore); 2007 Jul; 86(4):233-241. PubMed ID: 17632265
[TBL] [Abstract][Full Text] [Related]
20. Prognosis and management of polymyalgia rheumatica.
Jones JG; Hazleman BL
Ann Rheum Dis; 1981 Feb; 40(1):1-5. PubMed ID: 7469518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
